SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Baumann Pia)
 

Sökning: WFRF:(Baumann Pia) > Outcome in a prospe...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006289naa a2201033 4500
001oai:gup.ub.gu.se/109142
003SwePub
008240528s2009 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:c8827f47-7e02-4715-9cea-78859ae42e38
009oai:DiVA.org:uu-254513
009oai:prod.swepub.kib.ki.se:119053523
009oai:DiVA.org:liu-20169
0247 a https://gup.ub.gu.se/publication/1091422 URI
0247 a https://doi.org/10.1200/JCO.2008.21.56812 DOI
0247 a https://lup.lub.lu.se/record/14126922 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2545132 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1190535232 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-201692 URI
040 a (SwePub)gud (SwePub)lud (SwePub)uud (SwePub)kid (SwePub)liu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Baumann, Piau Karolinska Institutet4 aut
2451 0a Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
264 1c 2009
520 a PURPOSE: The impact of stereotactic body radiotherapy (SBRT) on 3-year progression-free survival of medically inoperable patients with stage I non-small-cell lung cancer (NSCLC) was analyzed in a prospective phase II study. PATIENTS AND METHODS: Fifty-seven patients with T1NOMO (70%) and T2N0M0 (30%) were included between August 2003 and September 2005 at seven different centers in Sweden, Norway, and Denmark and observed up to 36 months. SBRT was delivered with 15 Gy times three at the 67% isodose of the planning target volume. RESULTS: Progression-free survival at 3 years was 52%. Overall- and cancer-specific survival at 1, 2, and 3 years was 86%, 65%, 60%, and 93%, 88%, 88%, respectively. There was no statistically significant difference in survival between patients with T1 or T2 tumors. At a median follow-up of 35 months (range, 4 to 47 months), 27 patients (47%) were deceased, seven as a result of lung cancer and 20 as a result of concurrent disease. Kaplan-Meier estimated local control at 3 years was 92%. Local relapse was observed in four patients (7%). Regional relapse was observed in three patients (5%). Nine patients (16%) developed distant metastases. The estimated risk of all failure (local, regional, or distant metastases) was increased in patients with T2 (41%) compared with those with T1 (18%) tumors (P = .027). CONCLUSION: With a 3-year local tumor control rate higher than 90% with limited toxicity, SBRT emerges as state-of-the-art treatment for medically inoperable stage I NSCLC and may even challenge surgery in operable instances.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Aged
653 a Aged
653 a 80 and over
653 a Disease-Free Survival
653 a Dyspnea
653 a etiology
653 a Fatigue
653 a etiology
653 a Female
653 a Fibrosis
653 a etiology
653 a Humans
653 a Lung Neoplasms
653 a pathology
653 a surgery
653 a Male
653 a Middle Aged
653 a Neoplasm Recurrence
653 a Local
653 a Pleural Effusion
653 a etiology
653 a Prospective Studies
653 a Radiosurgery
653 a adverse effects
653 a methods
653 a Small Cell Lung Carcinoma
653 a pathology
653 a surgery
653 a Treatment Outcome
653 a MEDICINE
7001 a Nyman, Jan,d 19564 aut
7001 a Hoyer, Morten4 aut
7001 a Wennberg, Beritu Karolinska Institutet4 aut
7001 a Gagliardi, Giovannau Karolinska Institutet4 aut
7001 a Lax, Ingmaru Karolinska Institutet4 aut
7001 a Drugge, Ninniu Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut
7001 a Ekberg, Lars4 aut
7001 a Friesland, Signeu Karolinska Institutet4 aut
7001 a Johansson, Karl-Axelu Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut
7001 a Lund, Jo-Asmund4 aut
7001 a Morhed, Elisabeth4 aut
7001 a Nilsson, Kristina,d 1967-u Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)kristnil
7001 a Levin, Nina4 aut
7001 a Paludan, Merete4 aut
7001 a Sederholm, Christeru Östergötlands Läns Landsting,Linköpings universitet,Lungmedicin,Hälsouniversitetet,Lungmedicinska kliniken US4 aut0 (Swepub:liu)chrse81
7001 a Traberg, Anders4 aut
7001 a Wittgren, Lenau Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine4 aut0 (Swepub:lu)rfa-lwi
7001 a Lewensohn, Rolfu Karolinska Institutet4 aut
7102 a Karolinska Institutetb Institutionen för kliniska vetenskaper4 org
7730 t Journal of clinical oncology : official journal of the American Society of Clinical Oncologyg 27:20, s. 3290-6q 27:20<3290-6x 1527-7755x 0732-183X
8564 u http://www.ncbi.nlm.nih.gov/pubmed/19414667?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1200/JCO.2008.21.5681y FULLTEXT
8564 8u https://gup.ub.gu.se/publication/109142
8564 8u https://doi.org/10.1200/JCO.2008.21.5681
8564 8u https://lup.lub.lu.se/record/1412692
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-254513
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:119053523
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-20169

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy